(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Most loved Amusement Park for Small children: Which One Do You Suggest? - 2A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- 3Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- 4New method spots signs of Earth's primordial life in ancient rocks
- 5Coalition led by Iraqi PM al-Sudani wins parliamentary elections
- 4 African Vacationer Locations
- Firefighters rescue two Israelis trapped in vehicles on flooded roads in West Bank
- ‘Extraordinary’ Iron Age war trumpet uncovered in England
- My Excursion to Monetary Autonomy: Awesome ways to save cash
- 6 Novice Cameras for 2024: Ideal for New Picture takers
- The Golden Globes gift bag has nearly $1 million worth of swag for some winners and presenters. What's in it?
- No red, no long shorts: The fashion rules Joe Burrows lives by
- Want to make America healthy again? Stop fueling climate change
- Ultra-Orthodox protests erupt across Israel on haredi IDF enlistment day
